PMID- 38252140
OWN - NLM
STAT- MEDLINE
DCOM- 20240301
LR  - 20240301
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 59
IP  - 3
DP  - 2024 Mar
TI  - Prevalence and risk factors for medication-refractory reflux esophagitis in 
      patients with systemic sclerosis in Japan.
PG  - 179-186
LID - 10.1007/s00535-024-02076-0 [doi]
AB  - BACKGROUNDS: Patients with systemic sclerosis (SSc) often have esophageal 
      motility abnormalities and weak esophago-gastric junction (EGJ) barrier function, 
      which causes proton pump inhibitor (PPI)-refractory reflux esophagitis (RE). The 
      aims of this study were to clarify the current management of RE and prevalence 
      and risk factors of medication-refractory RE in patients with SSc in Japan. 
      METHODS: A total of 188 consecutive patients with SSc who underwent both 
      esophageal high-resolution manometry (HRM) and esophagogastroduodenoscopy (EGD) 
      were reviewed. The presence of RE and grades of the gastroesophageal flap valve 
      (GEFV) were assessed. Esophageal motility was assessed retrospectively according 
      to the Chicago classification v3.0. When RE was seen on a standard dose of PPI or 
      any dose of vonoprazan (VPZ), it was defined as medication-refractory RE. 
      RESULTS: Approximately 80% of patients received maintenance therapy with acid 
      secretion inhibitors regardless of esophageal motility abnormalities. 
      Approximately 50% of patients received maintenance therapy with PPI, and 
      approximately 30% of patients received VPZ. Medication-refractory RE was observed 
      in 30 patients (16.0%). In multivariable analyses, the number of EGD and absent 
      contractility were significant risk factors for medication-refractory RE. 
      Furthermore, combined absent contractility and GEFV grade III or IV had higher 
      odds ratios than did absent contractility alone. CONCLUSIONS: Patients with 
      persistent reflux symptoms and those with absent contractility and GEFV grade III 
      or IV should receive maintenance therapy with strong acid inhibition to prevent 
      medication-refractory RE.
CI  - (c) 2024. Japanese Society of Gastroenterology.
FAU - Kuribayashi, Shiko
AU  - Kuribayashi S
AUID- ORCID: 0000-0002-5067-552X
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine, 3-39-15 Showa-Machi Maebashi, Gunma, 371-8511, Japan. 
      shikokuri@gunma-u.ac.jp.
FAU - Nakamura, Fumihiko
AU  - Nakamura F
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine, 3-39-15 Showa-Machi Maebashi, Gunma, 371-8511, Japan.
FAU - Motegi, Sei-Ichiro
AU  - Motegi SI
AD  - Department of Dermatology, Gunma University Graduate School of Medicine, 
      Maebashi, Gunma, Japan.
FAU - Hara, Kenichiro
AU  - Hara K
AD  - Department of Allergy and Respiratory Medicine, Gunma University Graduate School 
      of Medicine, Maebashi, Gunma, Japan.
FAU - Hosaka, Hiroko
AU  - Hosaka H
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine, 3-39-15 Showa-Machi Maebashi, Gunma, 371-8511, Japan.
FAU - Sekiguchi, Akiko
AU  - Sekiguchi A
AD  - Department of Dermatology, Gunma University Graduate School of Medicine, 
      Maebashi, Gunma, Japan.
FAU - Ishikawa, Mai
AU  - Ishikawa M
AD  - Department of Dermatology, Gunma University Graduate School of Medicine, 
      Maebashi, Gunma, Japan.
FAU - Endo, Yukie
AU  - Endo Y
AD  - Department of Dermatology, Gunma University Graduate School of Medicine, 
      Maebashi, Gunma, Japan.
FAU - Harada, Tomonari
AU  - Harada T
AD  - Department of Cardiovascular Medicine, Gunma University Graduate School of 
      Medicine, Maebashi, Gunma, Japan.
FAU - Sorimachi, Hidemi
AU  - Sorimachi H
AD  - Department of Cardiovascular Medicine, Gunma University Graduate School of 
      Medicine, Maebashi, Gunma, Japan.
FAU - Obokata, Masaru
AU  - Obokata M
AD  - Department of Cardiovascular Medicine, Gunma University Graduate School of 
      Medicine, Maebashi, Gunma, Japan.
FAU - Uchida, Mitsuo
AU  - Uchida M
AD  - Department of Public Health, Gunma University Graduate School of Medicine, 
      Maebashi, Gunma, Japan.
FAU - Yamaguchi, Koichi
AU  - Yamaguchi K
AD  - Department of Allergy and Respiratory Medicine, Gunma University Graduate School 
      of Medicine, Maebashi, Gunma, Japan.
FAU - Uraoka, Toshio
AU  - Uraoka T
AD  - Department of Gastroenterology and Hepatology, Gunma University Graduate School 
      of Medicine, 3-39-15 Showa-Machi Maebashi, Gunma, 371-8511, Japan.
LA  - eng
GR  - JP18K15772/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20240122
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
SB  - IM
MH  - Humans
MH  - *Esophagitis, Peptic/drug therapy/epidemiology/etiology
MH  - Japan/epidemiology
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Scleroderma, Systemic/complications/drug therapy
MH  - Proton Pump Inhibitors
MH  - Manometry
MH  - *Pyrroles
MH  - *Sulfonamides
OTO - NOTNLM
OT  - Esophageal motility abnormalities
OT  - Proton pump inhibitor
OT  - Reflux esophagitis
OT  - Systemic sclerosis
OT  - Vonoprazan
EDAT- 2024/01/22 12:43
MHDA- 2024/03/01 06:45
CRDT- 2024/01/22 11:04
PHST- 2023/05/24 00:00 [received]
PHST- 2024/01/02 00:00 [accepted]
PHST- 2024/03/01 06:45 [medline]
PHST- 2024/01/22 12:43 [pubmed]
PHST- 2024/01/22 11:04 [entrez]
AID - 10.1007/s00535-024-02076-0 [pii]
AID - 10.1007/s00535-024-02076-0 [doi]
PST - ppublish
SO  - J Gastroenterol. 2024 Mar;59(3):179-186. doi: 10.1007/s00535-024-02076-0. Epub 
      2024 Jan 22.